173 related articles for article (PubMed ID: 29805697)
1. The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
Nishikawa K; Aoyama T; Oba MS; Yoshikawa T; Matsuda C; Munemoto Y; Takiguchi N; Tanabe K; Nagata N; Imano M; Oshiro M; Fukushima R; Kataoka M; Morita S; Tsuburaya A; Mishima H; Kono T; Sakamoto J
J Cancer; 2018; 9(10):1725-1730. PubMed ID: 29805697
[No Abstract] [Full Text] [Related]
2. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis.
Aoyama T; Nishikawa K; Takiguchi N; Tanabe K; Imano M; Fukushima R; Sakamoto J; Oba MS; Morita S; Kono T; Tsuburaya A
Cancer Chemother Pharmacol; 2014 May; 73(5):1047-54. PubMed ID: 24652604
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C; Munemoto Y; Mishima H; Nagata N; Oshiro M; Kataoka M; Sakamoto J; Aoyama T; Morita S; Kono T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):97-103. PubMed ID: 25983022
[TBL] [Abstract][Full Text] [Related]
4. The effect of Hangeshashinto on Oral Mucositis Caused by Induction Chemotherapy in Patients with Head and Neck Cancer.
Taira K; Fujiwara K; Fukuhara T; Koyama S; Takeuchi H
Yonago Acta Med; 2020 Aug; 63(3):183-187. PubMed ID: 32884437
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis.
Kono T; Satomi M; Chisato N; Ebisawa Y; Suno M; Asama T; Karasaki H; Matsubara K; Furukawa H
World J Oncol; 2010 Dec; 1(6):232-235. PubMed ID: 29147213
[TBL] [Abstract][Full Text] [Related]
7. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
8. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
Yamazaki K; Ariyoshi N; Miyauchi H; Ohira G; Kaneya N; Yamamoto K; Arai K; Yamazaki S; Matsubara H; Suzuki T; Ishii I
J Clin Pharm Ther; 2019 Dec; 44(6):946-951. PubMed ID: 31407827
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
[TBL] [Abstract][Full Text] [Related]
13. A traditional Japanese medicine--Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion.
Yamashita T; Araki K; Tomifuji M; Kamide D; Tanaka Y; Shiotani A
Support Care Cancer; 2015 Jan; 23(1):29-35. PubMed ID: 24943276
[TBL] [Abstract][Full Text] [Related]
14. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
[TBL] [Abstract][Full Text] [Related]
15. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Peterson DE; Barker NP; Akhmadullina LI; Rodionova I; Sherman NZ; Davidenko IS; Rakovskaya GN; Gotovkin EA; Shinkarev SA; Kopp MV; Kulikov EP; Moiseyenko VM; Gertner JM; Firsov I; Tuleneva T; Yarosh A; Woon CW
J Clin Oncol; 2009 Sep; 27(26):4333-8. PubMed ID: 19636011
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial.
Okada K; Kawai M; Hirono S; Fujii T; Kodera Y; Sho M; Nakajima Y; Satoi S; Kwon AH; Shimizu Y; Ambo Y; Kondo N; Murakami Y; Ohuchida J; Eguchi H; Nagano H; Oba MS; Morita S; Sakamoto J; Yamaue H;
Surgery; 2016 May; 159(5):1333-41. PubMed ID: 26747224
[TBL] [Abstract][Full Text] [Related]
18. Effects of Topical Hangeshashinto (TJ-14) on Chemotherapy-Induced Oral Mucositis.
Ozawa N; Onda T; Hayashi K; Honda H; Shibahara T
Cancer Manag Res; 2020; 12():1069-1078. PubMed ID: 32104087
[TBL] [Abstract][Full Text] [Related]
19. Effects of a Plantago ovata-based herbal compound in prevention and treatment of oral mucositis in patients with breast cancer receiving chemotherapy: A double-blind, randomized, controlled crossover trial.
Hasheminasab FS; Hashemi SM; Dehghan A; Sharififar F; Setayesh M; Sasanpour P; Tasbandi M; Raeiszadeh M
J Integr Med; 2020 May; 18(3):214-221. PubMed ID: 32268991
[TBL] [Abstract][Full Text] [Related]
20. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM
Lancet Oncol; 2016 Feb; 17(2):212-223. PubMed ID: 26727163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
